# Pemvidutide

> Pemvidutide is an investigational dual GLP-1/glucagon receptor agonist studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Early- and mid-stage trials have reported average body-weight reductions along with improvements in liver fat markers, generally without the extended dose titration reported for some comparable agents. It remains in clinical development and has not received regulatory approval. Data are currently limited to trial populations.

- URL: https://www.lifeconverted.com/peptides/pemvidutide
- Also known as: ALT-801
- Primary category: Weight Management
- Effectiveness rank: #18 in Weight Management
- Evidence level: Moderate evidence
- Route: Subcutaneous
- Dose range: 1.2-2.4 mg
- Dose tiers: low 1.2 mg; moderate 1.8 mg; high 2.4 mg
- Half-life: Approximately 5-6 days, consistent with once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous use per trial protocols on, Not established outside of trial settings off
- Storage: Refrigerate at 2-8°C; protect from light; do not freeze.

## Mechanism of action

Pemvidutide activates GLP-1 receptors, reducing appetite and slowing gastric emptying, while also engaging glucagon receptors, thought to promote hepatic fat oxidation and energy expenditure. It is engineered with a balanced receptor activity ratio intended to support both weight reduction and liver-fat improvement.

## Reported benefits

- Associated with meaningful average weight loss in early-phase trials
- May reduce liver fat content
- Once-weekly dosing schedule
- Dual-pathway mechanism targeting appetite and hepatic fat metabolism

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during titration
- Decreased appetite
- Injection-site reactions
- Potential increases in heart rate reported in some trials
- Long-term safety data remain limited

## Common protocols

- Once-weekly subcutaneous injection used in trial protocols with minimal titration reported in some studies

## Stacking notes

Not established; combination with other incretin-based agents is not supported by published research.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer